BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Dec 28, 2015; 7(12): 494-500
Published online Dec 28, 2015. doi: 10.4329/wjr.v7.i12.494
Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy
Masatsugu Iwamura, Kazushige Hayakawa, Shiro Baba, Masashi Kitano, Tetsuo Fujita, Kazumasa Matsumoto, Shinji Kurosaka, Ken-ichi Tabata, Shuhei Hirano, Hiromichi Ishiyama, Takefumi Satoh, Hideyasu Tsumura
Hideyasu Tsumura, Takefumi Satoh, Shuhei Hirano, Ken-ichi Tabata, Shinji Kurosaka, Kazumasa Matsumoto, Tetsuo Fujita, Shiro Baba, Masatsugu Iwamura, Department of Urology, Kitasato University School of Medicine, Sagamihara 252-0374, Japan
Hiromichi Ishiyama, Masashi Kitano, Kazushige Hayakawa, Department of Radiation Oncology, Kitasato University School of Medicine, Sagamihara 252-0374, Japan
Author contributions: Tsumura H performed the majority of the work including collecting, analyzing, and interpreting the data and writing the report; Ishiyama H, Hirano S, Kurosaka S and Kitano M contributed to collecting the data; Tabata K, Matsumoto K and Fujita T were participated in analyzing and interpreting the data; Satoh T, Baba S, Hayakawa K and Iwamura M designed and coordinated the study.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Kitasato University School of Medicine and Kitasato University Hospital (B14-21).
Informed consent statement: This retrospective study was performed under IRB approval, all data is de-identified for statistical analysis. Therefore, we think that a waiver of informed consent may be justifiable under this situation.
Conflict-of-interest statement: Dr. Tsumura received honoraria for lecture fees from Nihon Medi-Physics Co, Ltd. Astellas Pharma Inc, and Takeda Pharmaceutical Co, Ltd. Drs Satoh, Ishiyama and Hayakawa received honoraria for lecture fees from Medicon Co, Ltd, and Nihon Medi-Physics Co, Ltd.
Data sharing statement: No additional data are available.
Correspondence to: Hideyasu Tsumura, MD, Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato Minami-ku, Sagamihara 252-0374, Japan. tsumura@med.kitasato-u.ac.jp
Telephone: +81-42-7789091 Fax: +81-42-7789374
Received: May 8, 2015
Peer-review started: May 9, 2015
First decision: July 27, 2015
Revised: August 13, 2015
Accepted: October 12, 2015
Article in press: October 12, 2015
Published online: December 28, 2015
Processing time: 233 Days and 16.8 Hours
Core Tip

Core tip: We evaluated the time course of testosterone recovery and the prognostic factors associated with prolonged testosterone recovery after the cessation of long-term (≥ 36 mo) androgen deprivation therapy in patients treated with brachytherapy. Five years after cessation, 22.6% of patients maintained a castrate testosterone level. We should consider this delay when determining therapeutic effects. Lower testosterone levels at cessation were significantly associated with prolonged testosterone recovery.